NIKKEI 225
38,644.09 +11.07 (+0.03%) HANG SENG
17,994.81 -340.51 (-1.86%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,376.10 +7.10 (+0.30%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
50,948.59 -598.55 (-1.16%)
BetterLife Pharma Inc. (NPAU.F)
| Previous close | 0.0780 |
| Open | 0.0765 |
| Bid | 0.0725 x N/A |
| Ask | 0.0915 x N/A |
| Day's range | 0.0765 - 0.0765 |
| 52-week range | 0.0240 - 0.0905 |
| Volume | |
| Avg. volume | 219 |
| Market cap | 10.184M |
| Beta (5Y monthly) | 1.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings date | 26 Jun 2024 - 01 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireBetterLife Announces Closing of a Private Placement
VANCOUVER, British Columbia, June 14, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has closed a non-brokered private placement, previously announced on May 3, 2024, pursuant to which the Company issued 5,300,000 units (“Units”) at a price of $0.10 per Unit for aggrega
- GlobeNewswire
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announced it has completed its animal GLP cardiopulmonary safety study of BETR-001. The study demonstrated that oral BETR-001 at doses over 100-fold the projected starting dose in upcoming human trials di
- GlobeNewswire
BetterLife Announces Intent to Complete Private Placement of Units
VANCOUVER, British Columbia, May 03, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to complete a Non-Brokered Private Placement offering (the “Private Placement”) of up to $500,000. The Company intends to use the proceeds for the advancement
